{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:44:51Z","timestamp":1787503491397,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","issue":"4-6","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1053\/j.seminoncol.2021.11.003","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:13:34Z","timestamp":1637885614000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia"],"prefix":"10.1053","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-4835","authenticated-orcid":false,"given":"Artem","family":"Oganesyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-0009","authenticated-orcid":false,"given":"Nerses","family":"Ghahramanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsene","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-7338","authenticated-orcid":false,"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yervand","family":"Hakobyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2021.11.003_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up y behalf of the EHA Guidelines Committee and ESMO Guidelines Committee","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0002","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0003","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0004","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0005","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0006","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0007","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival, a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0008","unstructured":"The World Bank. Life expectancy at birth, total (years) \u2013 Armenia. 2020. Available at: https:\/\/data.worldbank.org\/indicator\/SP.DYN.LE00.IN?locations=AM Accessed September 8, 2021."},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0009","series-title":"Global Health Observatory data repository | Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%) - Data by country","year":"2021"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0010","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1186\/s12885-021-08676-w","article-title":"Multiple myeloma in Armenia during the period 2006-2018: facts and discussion","volume":"21","author":"Ghazaryan","year":"2021","journal-title":"BMC cancer"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0011","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Storti","year":"2018","journal-title":"Found Haematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0012","unstructured":"National Cancer Institute. Cancer Stat Facts: Myeloma. Surveillance, Epidemiology, and End Results [SEER] Cancer Statistics Review 2021. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html Accessed August 23, 2021."},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0013","article-title":"Krebs in Deutschland f\u00fcr 2015 \/2016","author":"Kaatsch","year":"2019","journal-title":"Robert Koch Inst"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0014","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1182\/blood.V128.22.5978.5978","article-title":"Geographical disparities in multiple myeloma survival in three french regions","volume":"128","author":"Mounier","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0015","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0016","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ajh.10003","article-title":"Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation","volume":"68","author":"Fonseca","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/CMAR.S126136","article-title":"Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions","volume":"9","author":"Nwabuko","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0018","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0019","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the international staging system superior to the Durie\u2013Salmon staging system? a comparison in multiple myeloma patients undergoing autologous transplant","volume":"238","author":"Hari","year":"2009","journal-title":"Leuk"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0020","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0021","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0022","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0023","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ejh.12556","article-title":"Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse","volume":"96","author":"Radocha","year":"2016","journal-title":"Eur.J Haematol."},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0025","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"international myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0026","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0027","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0028","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0029","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0030","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41409-019-0478-4","article-title":"Efficacy and safety of autologous stem cell transplantation in patients aged \u2265 65 years with multiple myeloma in the era of novel agents","volume":"54","author":"Mizuno","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0031","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3324\/haematol.2016.150334","article-title":"Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study","volume":"101","author":"Garderet","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0032","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.2016.151860","article-title":"Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial","volume":"101","author":"Straka","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0033","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75\u2009years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0034","first-page":"559","article-title":"Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for primetime","volume":"17","author":"Kazandjian","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0035","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0036","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0037","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0038","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0039","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0040","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0041","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0042","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J ClinOncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0043","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0044","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ejh.13349","article-title":"The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"104","author":"Okazuka","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0045","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"Okazuka","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0046","first-page":"1759","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"19","author":"Palumbo","year":"2017","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BSR20170304","article-title":"Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis","volume":"37","author":"Sun","year":"2017","journal-title":"Biosci Rep"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0298-1","article-title":"Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0049","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0051","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0052","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0054","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2017","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0055","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0056","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0057","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/ejh.13147","article-title":"Bortezomib-based therapy for relapsed\/refractory multiple myeloma in real-world medical practice","volume":"101","author":"Terpos","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0058","doi-asserted-by":"crossref","first-page":"23704","DOI":"10.18632\/oncotarget.25281","article-title":"Efficacy and safety of carfilzomib in relapsed and\/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials","volume":"9","author":"Shah","year":"2018","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0059","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3324\/haematol.2019.217448","article-title":"Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies","volume":"105","author":"Mateos","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0060","first-page":"103","article-title":"Social frailty predicts worse outcomes in patients with multiple myeloma: a novelty in an old approach","volume":"1","author":"Terao","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0061","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0062","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0063","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","article-title":"Changing clinical presentation of multiple myeloma","volume":"27","author":"Riccardi","year":"1991","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0064","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"international myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34:","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0065","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1179\/102453312X13336169156933","article-title":"Thrombosis in multiple myeloma (MM)","volume":"17","author":"Cesarman-Maus","year":"2012","journal-title":"Hematology"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0066","first-page":"1","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0067","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0068","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S2214-109X(18)30086-X","article-title":"Supportive care in cancer: new directions to achieve universal access to psychosocial, palliative, and end-of-life care","volume":"6","author":"Kaasa","year":"2018","journal-title":"Lancet Glob Heal"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0069","first-page":"1","article-title":"Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiency","volume":"101","author":"Hanna","year":"2010","journal-title":"BMC Int Heal Hum Rights"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0070","first-page":"991","article-title":"Availability of essential medicines for pediatric oncology in Armenia, Asian Pac","volume":"20","author":"Simonyan","year":"2019","journal-title":"J Cancer Prev"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0071","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0072","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1200\/JCO.18.00371","article-title":"The Road Home","volume":"36","author":"Tamamyan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0073","first-page":"1","article-title":"Global perspectives on palliative care for cancer patients: not all countries are the same","volume":"23","author":"Brant","year":"2021","journal-title":"Curr Oncol. Reports"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0074","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/cncr.31305","article-title":"Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico","volume":"124","author":"Tar\u00edn-Arzaga","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0075","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41409-020-0826-4","article-title":"The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus","volume":"55","author":"Passweg","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0076","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0077","first-page":"421","article-title":"FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials","volume":"8","author":"Sundaram","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0078","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/ageing\/afy177","article-title":"The use of an electronic health record system reduces errors in the National Hip Fracture Database","volume":"48","author":"Lawrence","year":"2019","journal-title":"Age Ageing"},{"key":"10.1053\/j.seminoncol.2021.11.003_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","article-title":"Electronic health records to facilitate clinical research","volume":"106","author":"Cowie","year":"2017","journal-title":"Clin Res Cardiol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775421000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775421000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:56:45Z","timestamp":1758805005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775421000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":79,"journal-issue":{"issue":"4-6","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0093775421000737"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2021.11.003","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}